(Q30244019)

12 June 2017

1 reference

title

Rheumatoid arthritis. (English)

1 reference

12 June 2017

1 reference

1

Josef S Smolen

1 reference

12 June 2017

2

Daniel Aletaha

1 reference

12 June 2017

3

Iain B McInnes

1 reference

12 June 2017

language of work or name

English

0 references

publication date

3 May 2016

1 reference

12 June 2017

1 reference

12 June 2017

volume

388

1 reference

12 June 2017

issue

10055

1 reference

12 June 2017

page(s)

2023-2038

1 reference

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Epidemiology and genetics of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Twin concordance rates for rheumatoid arthritis: results from a nationwide study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

To what extent is the familial risk of rheumatoid arthritis explained by established rheumatoid arthritis risk factors?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Psoriasis genetics: breaking the barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Genetics of rheumatoid arthritis contributes to biology and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Epigenetics in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Personality, socio-economic status and inflammation: cross-sectional, population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Education, self-care, and outcomes of rheumatic diseases: further challenges to the "biomedical model" paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

HLA molecules, bacteria and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

New therapies for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The microbiome in infectious disease and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Activation of the classical pathway of complement by rheumatoid factors. Assessment by radioimmunoassay for C4

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Intracellular signal pathways: potential for therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Therapeutic strategies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Osteoclasts are essential for TNF-alpha-mediated joint destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Metalloproteases and inhibitors in arthritic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Asymptomatic synovitis precedes clinically manifest arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Extraarticular manifestations of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

A review of methotrexate-induced accelerated nodulosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Doppler ultrasound findings in healthy wrists and finger joints

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Therapies for active rheumatoid arthritis after methotrexate failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Tuberculosis associated with therapy against tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Forget personalised medicine and focus on abating disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The JAK-STAT pathway: impact on human disease and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Tofacitinib versus methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Baricitinib in Patients with Refractory Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Management of RA medications in pregnant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Metabolomics for rheumatic diseases: has the time come?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930173-8

7 January 2021

10.1016/S0140-6736(16)30173-8

Identifiers

DOI

1 reference

12 June 2017

1 reference